



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> <b>A61B 19/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/40867</b> <b>(43) International Publication Date:</b> 19 August 1999 (19.08.99)
<b>(21) International Application Number:</b> PCT/US99/02990 <b>(22) International Filing Date:</b> 12 February 1999 (12.02.99) <b>(30) Priority Data:</b> 09/023,062 13 February 1998 (13.02.98) US <b>(71)(72) Applicant and Inventor:</b> RODRIGUEZ, Victorio, C. [US/US]; 7791 Hoertz Road, Parma, OH 44134 (US). <b>(74) Agent:</b> COHN, Howard, M.; Suite 110, 23360 Chagrin Boulevard, Cleveland, OH 44122-5537 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TREATMENT OF BRAIN EDEMA USING CARBONIC ANHYDRASE ENZYME INHIBITOR  <b>(57) Abstract</b>  <p>A method for treating victims of cerebral edema is presented that includes the intravenous injection of a carbonic anhydrase enzyme inhibitor that passes through the blood-brain barrier, such as acetazolamide (A.K.A., DIAMOX®), which is a readily-available and often-prescribed diuretic. Such edema, or brain swelling may be caused as a result of ischemic strokes especially, but also swelling due to tumors, surgeries, or cerebral trauma. It is preferred to combine the a carbonic anhydrase enzyme inhibitor therapy with hyperventilation of the lungs, even including the use of supplemental oxygen, thereby to reduce the concentration of carbon dioxide in the blood and hence in the brain.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## TREATMENT OF BRAIN EDEMA USING CARBONIC ANHYDRASE ENZYME INHIBITOR

5           This application is a Continuation-in-Part of U. S. Patent application Serial No. 08/490,110, filed June 07, 1996, copending herewith and included in its entirety by reference herein.

**INTRODUCTION**

10           This invention relates to the medical treatment of victims of cerebral edema, and especially to the relief of brain swelling as a result of ischemic strokes especially, but also swelling due to tumors, surgeries, or cerebral trauma, which swelling usually results in severe disability  
15 and often death of the patient. More particularly, this invention relates to the therapeutic use of a carbonic anhydrase enzyme inhibitor that passes through the blood-brain barrier, such as acetazolamide as a medication to relieve such brain swelling or edema. Acetazolamide is a  
20 commonly-prescribed diuretic distributed under the trade names DIAMOX® acetazolamide SEQUELS® sustained release capsules, DIAMOX® acetazolamide tablets, and DIAMOX® sterile acetazolamide sodium parenteral (supplied as a sodium salt). DIAMOX® and SEQUELS® are registered trade marks of Lederle  
25 Laboratories Division of American Cyanamid Company.

Ischemic strokes are the result of a sudden

compromising of the blood supply to the brain, that often causes brain cell swelling, abnormal electric discharges from the brain, and brain death. Whereas the causative factor in the compromising of the blood supply to the brain may be transient, as small emboli that occlude a vessel and then pass on, allowing blood flow to be reestablished. How often such transient ischemic attacks result in completed stroke (i.e., with no immediate progression or regression of symptoms) is unknown. Some patients with such attacks develop strokes; in others, the symptoms disappear without sequelae. Even transient ischemic attacks can produce brain cell swelling, a symptom that carries its own potential death threat.

#### **PRIOR ART**

- Today's management of stroke involves several steps that are taken as the need becomes apparent:
- a. Airway support and ventilatory assistance are given to patients with depressed levels of consciousness; supplemental oxygen is used for hypoxic patients.
  - b. Caution is recommended in the use of any antihypertensive agents.
  - c. The Stroke Council of the American Heart Association disapproved the use of corticosteroids for cerebral edema and increased intracranial pressure after stroke, noting that conventional

and large doses of corticosteroids in clinical trials showed no improvement.

5 d. Osmotherapy and hyperventilation are recommended for patients whose condition is deteriorating as a secondary effect to increased intracranial pressure.

e. The Stroke Council stressed that data about the safety and efficacy of heparin in ischemic strokes was insufficient and conflicting, potentially  
10 dangerous, noting the frequency of parenchymal hemorrhage.

f. The panel also refused to recommend the use of nimodipine, barbiturates, naloxone, glutamate antagonists, or amphetamines.

15 U.S. Patent No. 5,389,630 was issued February 14, 1995, to Sato, et al., claiming an array of certain diamine compounds and their use for treating disorders of cerebral function or preventing the progress of such disorders, including cerebral hemorrhage, cerebral infarction,  
20 subarachnoid hemorrhage, transient ischemic attack, cerebrovascular disorders, and the like. The Sato et al. patent illustrates efficacy by means of tests on animals.

Prior art is available (U.S. patents 4,463,208, Cragoe, Jr. et al.; and 4,463,850, Cragoe, Jr. et al.) that teaches  
25 the use of acetolamide in treating animal subjects suffering from brain edema caused by trauma, but it is known that

human subjects differ from animal subjects in that the blood-brain barrier in humans is quite complete, as compared with that of animals. This blood-brain barrier is effective in blocking bloodstream chemicals and many medications from  
5 reaching and affecting the cells of the brain. In contrast, the blood-brain barrier in animals is incomplete. Thus, results of testing of chemicals that affect the brain cells of animals do not necessarily translate directly to results that would be obtained in human testing.

10       Accordingly, cerebral protective drugs that promise excellent clinical effect and are readily available and useful for oral or intravenous administration are to be desired. Applicant believes that the present invention meets that need.

**DETAILED DESCRIPTION OF THE INVENTION**

It is believed that at least part of the damage done during brain edema from ischemic stroke and other trauma is due to the formation of bicarbonates in the cells, which  
5 reaction is accelerated by the presence of carbonic anhydrase. Inhibitors for carbonic anhydrase are known: acetazolamide and dichlorophenamide are among them. The former is a commonly-prescribed diuretic, especially useful for short-term use, as its effectiveness diminishes after 2  
10 or 3 days. It is marketed under the trade name DIAMOX® by Lederle Laboratories Division of American Cyanamid Company. The simplified chemical formula for acetazolamide is  $C_4H_6N_4O_3S_2$  and the chemical name that is believed to abide by the naming rules of the International Union of Chemistry is:

15 N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)-acetamide

Acetazolamide, as an enzyme inhibitor, acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid:



Affecting this reaction is said to be the source of the diuretic effect in the kidney. The result is renal loss of bicarbonate (i.e.,  $HCO_3^-$ ) ion, which carries out sodium, water, and potassium.

25 In addition, there are reports of evidence seems to indicate that acetazolamide does have utility as an adjuvant

in the treatment of certain dysfunctions of the central nervous system (e.g., epilepsy). Inhibition of carbonic anhydrase in this area appears to retard abnormal, paroxysmal excessive discharge from central nervous system neurons. No prior art is known that would suggest the use of these carbonic anhydrase enzyme inhibitors specifically for the treatment of human stroke victims, or human victims of other cerebral swelling or trauma. Nothing indicates that acetazolamide would be a cerebral protective drug of value in treating such human victims.

The efficacy of this therapeutic treatment would likely be considered by medical researchers to be anecdotal, not being a part of a statistically-designed double-blind clinical experiment, but the success rate in the last-resort use of acetazolamide on patients who were otherwise thought to be terminal, has led this investigator to seek patent protection for the treatment method.

Results from twelve patients having various brain disorders who were, as a last resort, treated with intravenous injections of a solution containing 500 mg of acetazolamide in 5 ml of sterile water. Initially, the dosage administered was 2.5 ml of this solution; eventually, the full 5 ml injection was used. The injections were continued daily for 2 - 3 days. This treatment was used with hyperventilation of the lung (even using supplemental oxygen), thereby to reduce the carbon dioxide (CO<sub>2</sub>) content

and raise the oxygen ( $O_2$ ) content in the blood and hence in the brain--whether or not the patient had been hypoxic--and diuresis to remove excess water (a further effect of the acetazolamide, although other diuretics may be employed).

5 The goal was to drive the reversible reaction of Equation 1 to the left, thereby to reduce the amount of bicarbonate ion formed and to slow further formation of bicarbonate. The twelve cases cited included: six cerebral infarctions, one of which exhibited acute hydrocephali; two intracranial  
10 hemorrhages; one malignant meningiomas; one other tumor that involved a brain hematoma; one anoxic encephalopathic coma; and one case of thyroid coma with brain swelling. Those cases involving tumors that were removed included post-surgical edema. All patients survived the crisis that  
15 prompted the last-resort treatment with acetazolamide. All were believed to be in terminal stages of their respective crisis situations, allowing for emergency measures in an attempt to prolong life. No patients treated by this method during this period of testing did not show improvement and  
20 ultimate recovery from the respective crisis conditions.

Based upon the limited experience cited above, the method for treatment of ischemic stroke that is sought to be protected comprises the initial administration of a carbonic anhydrase enzyme inhibitor that passes through the  
25 blood-brain barrier, such as acetazolamide, by intravenous injection and additional doses of said carbonic anhydrase

enzyme inhibitor that is either administered orally (i.e., by ingestion) or injected intravenously. In the preferred mode, the use of acetazolamide is combined with continued hyperventilation of the lungs. Diuresis, using a diuretic

5 other than a carbonic anhydrase enzyme inhibitor, is recommended. Dosage of acetazolamide to be recommended may vary depending upon the perceived severity of the ischemic stroke as well as upon body weight of the patient, but an initial dose of between 250 and 500 mg with supplemental  
10 doses of between 250 and 500 mg per day, administered orally (i.e., by ingestion) or by injection, are believed to be efficacious. The dosage suitable for other carbonic anhydrase enzyme inhibitors will depend upon their efficacy or potency for this use.

15 Having described this invention, including the citing of functional specific examples thereof, applicant desires to include within the scope of his invention those improvements that would be immediately obvious to one skilled in the art, some, but not all of which improvements  
20 may have been referred to herein. Applicant desires the breadth of his invention to be limited only by the scope of the claims appended hereto.

**CLAIMS**

I claim:

5           1. Use of a carbonic anhydrase enzyme inhibitor that passes through the blood-brain barrier in the manufacture of a medicament for the treatment of a human patient suffering from the effects of brain edema.

10           2. The use of Claim 1 wherein said medicament comprises an intravenously injectable mixture comprising said carbonic anhydrase enzyme inhibitor and sterile water.

          3. The use of Claim 2 wherein said mixture comprises  
15 approximately 500 milligrams of a carbonic anhydrase enzyme inhibitor and approximately 5 milliliters of sterile water.

          4. The use of Claim 2 wherein said mixture is a solution, said carbonic anhydrase enzyme inhibitor is a  
20 solute, and said water is a solvent.

          5. The use of Claim 2 wherein said mixture comprises approximately 250 to 500 milligrams of a carbonic anhydrase enzyme inhibitor and approximately 2.5 to 5 milliliters of  
25 sterile water.

6. The use of Claim 5 wherein said mixture is a solution, said carbonic anhydrase enzyme inhibitor is a solute, and said water is a solvent.

5        7. The use of Claim 1 wherein said medicament is suitable for administration to said patient by ingestion.

8. The use of Claim 1 wherein a first dose of said medicament is suitable for administration as by intravenous  
10 injection and a subsequent dose by ingestion.

9. The use of Claims 1, 2, 7, or 8 wherein said medicament is suitable for administration along combined with hyperventilating the patient.  
15

10. The use of Claim 1 wherein said medicament is administered to a human patient suffering from the effects of brain edema caused by ischemic stroke.

20        11. The use of claim 9 wherein said hyperventilating is increasing the concentration of oxygen in respiratory air.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/02990

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61B 19/00

US CL : 128/898

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/897, 898; 514/869-871

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,463,208 A (CRAGOE, JR. et al) 31 July 1984, entire document.	1-11
A	US 4,465,850 A (CRAGOE, JR. et al) 14 August 1984, entire document.	1-11
A	US 5,389,630 A (SATO et al) 14 February 1995, entire document.	1-11



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 APRIL 1999

Date of mailing of the international search report

25 MAY 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN LACYK

Telephone No. (703) 308-2995